SNI Blog

SNI Blog

Swedish Named a Leap Frog Top Hospital

Karen Pabillon

The Leapfrog Group Announces Annual Top Hospitals List

The Leapfrog Group’s annual class of top hospitals – 65 from a field of nearly 1,200 – was announced today in Washington, D.C. and, for the first time, included Swedish Medical Center’s First Hill and Cherry Hill campuses. The announcement came at Leapfrog’s 10th anniversary meeting. A complete list of 2010 Leapfrog Top Hospitals can be viewed at www.leapfroggroup.org.

The Leapfrog Group is a coalition of public and private purchasers of employee health coverage – including Boeing and the Washington State Healthcare Authority – which was founded a decade ago to work for improvements in health-care safety, quality and affordability. Initially organized by the Business Roundtable, it is now an independent advocacy group working with a broad range of partners, including hospitals and insurers.

The ‘Top Hospital’ selection is based on the results of the Leapfrog Group’s national survey, which launched in 2001. It measures hospitals’ performance in crucial areas of patient safety and quality, including:

  • The use of computer physician order entry (CPOE) to prevent medication errors;
  • Standards for doing high-risk procedures such as heart surgery;
  • Protocols and policies to reduce medical errors and other safe practices recommended by the National Quality Forat um; and
  • Adequate nurse and physician staffing

The results of the survey are posted www.leapfroggroup.org.

SNI Grand Rounds Series 2010 - MRI of Carotid Atherosclerosis and it's Role in Predicting Stroke/TIA

Karen Pabillon
Thursday, December 2, 2010
7:30 to 8:30 a.m.
Swedish Education and Conference Center, Room B

Presented By: Chun Yuan, Ph.D., Professor of Radiology, Adjunct Professor of Bioengineering, University of Washington Objectives: At the conclusion of this session, attendees will have an incresed ability to:

  • Describe the need for plaque characterization in identifying high risk lesions
  • Recall current MRI-based plaque imaging technique and it's ability for plaque characterization

SNI Grand Rounds Series is every 1st and 3rd Thursday of each month

SNI Grand Rounds Series 2010 - Novel Surgical Approaches to Traditional Neuro-Thoracic Diseases

Karen Pabillon
Thursday, November 18, 2010
7:30 to 8:30 a.m.
Swedish Education and Conference Center, Room B

Brian Louie, MD, FRCSC, FACS, Esophageal Surgery, Thoracic Surgery

Objectives:

At the conclusion of this session, attendees will have an increased ability to:

  • Review the role of thymectomy in the management of myasthenia gravis and describe the options for thymectomy
  • Discuss the management of thoracic neurogenic tumors and options for surgical treatment
  • Discuss the role and outcomes of thoracic sympathectomy for hyperhidrosis

SNI Grand Rounds Series is every 1st and 3rd Thursday of each month.

Multiple Sclerosis Center Continues to Grow

James D. Bowen, MD

The Multiple Sclerosis Center continues to grow. We have added an additional MS nurse, Reiko Aramaki, RN. Reiko joined us from the Evergreen MS Center. She is certified by the International Order of MS Nurses and will expand our ability to respond to patient’s needs.

Outreach programs also continue. Dr. Bowen was recently interviewed by Kathi Goertzen from KOMO TV4 regarding CCSVI. This interview can be seen at http://www.komonews.com/home/video/106166123.html.

Also, Chaz Gilbert, a patient care coordinator won the Seattle Verizon Urban Challenge on 10/30/10, racing through 12 checkpoints in their city using only clues, their feet and public transit.

New center brings tertiary neurological care to children

Karen Pabillon

The Pediatric Epilepsy and Pediatric Neurology services at Swedish Medical Center have combined to create the new Swedish Pediatric Neuroscience Center. As part of the Swedish Neuroscience Institute (SNI), comprehensive neurological care for newborns, infants, children and adoles­cents is now located at the Swedish First Hill campus in Seattle. Marcio Sotero de Menezes, M.D., has been appointed direc­tor of the new center.

The center has a high patient volume for the medical and surgical treatment of seizure disorders, including complex epi­lepsy syndromes and genetic epilepsies. It is accredited by the National Association of Epilepsy Centers as a Level-4 epilepsy center.

In addition to epilepsy, the center’s specialists treat pediatric patients for a wide range of neurological disorders, in­cluding headache and migraine; move­ment disorders, tics and Tourette’s syn­drome; genetic and metabolic disorders; neurodevelopmental disorders and learn­ing disabilities; brain malformations; cere­bral palsy; stroke; tuberous sclerosis; and neurofibromatosis.

The center’s pa­tients will also benefit from a broad spectrum of pediatric neurol­ogy inpatient hospital services, including epilepsy monitoring unit, pediatric and neonatal intensive care units, procedural seda­tion services, pediatric neurosurgery and intraoperative EEG monitoring, imaging services, and neuropsychological testing. Physical, occupational and speech therapy services are also available to the center’s patients.

For more information about the Swedish Pediatric Neuroscience Center, please call 206-215-1440.

Exciting Advances in Multiple Sclerosis from ECTRIMS

Karen Pabillon

There is exciting news from last week’s 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

ALEMTUZUMAB. 5-year data from a Phase II extension study for alemtuzumab, an intravenously administered monoclonal antibody, showed that the drug:

  • reduced annualized rate of relapse to 0.14 compared with 0.28 for interferon
  • reduced the risk for sustained accumulation of disability in remitting relapsing multiple sclerosis by 87% compared to 62% with interferon.

This is a remarkable agent with excellent activity in MS. Adverse events included immune thrombocytopenic purpura, thyroiditis and anti-glomerular basement membrane disease.

TERIFLUNOMIDE. A Phase III trial of oral teriflunomide in remitting relapsing MS showed:

  • a 31% reduction in relapse rate and increased time to first relapse compared with placebo
  • reduced the risk of sustained disability progression by 29.8%.

Side effects were mild and included diarrhea, nausea, liver function abnormalities and hair loss.

Alemtuzumab and teriflunomide are currently in Phase III clinical trials at SNI.

SNI PRESENTATIONS:

  • Dr. Jim Bowen presented a poster about ongoing demyelination and neurodegeneration in a patient who had undergone autologous stem cell transplantation.
  • Drs. Jung Henson and Mayadev reviewed the beneficial effects of exercise on functional and quality of life outcomes from SNI’s MS wellness program

Clinical Neurophysiology Lab Receives Accreditation

Karen Pabillon

Congratulations are in order for the Clinical Neurophysiology Laboratory for attaining Accreditation by the EEG Laboratory Accreditation board of ABRET. We are the first and only Lab to receive Accreditation in Washington State and one of only 10 labs west of the Mississippi. Accreditation means the Lab has met strict standards and is recognized as a place where patients and physicians can have confidence they are receiving quality diagnostics. Thanks for all the great work and CONGRATULATIONS to everyone on the team who made this possible!

-Colleen Douville

Director for Cerebrovascular Ultrasound
Program Manager for Clinical Neurophysiology

The neurophysiology laboratory at Swedish is a critical component to the Epilepsy program.

Results 50-56 of 67

Top Authors

Karen Pabillon
John W Henson IV

John W Henson IV
Director, Neurology

Peggy Shortt, MN, ARNP

Peggy Shortt, MN, ARNP
Manager, Swedish Deep Brain Stimulation Program

Erin Kieper

Erin Kieper
Program Development Manager, Swedish Radiosurgery Center